Literature DB >> 20122606

Mortality risk in splenectomised patients: a Danish population-based cohort study.

Mellissa Yong1, Reimar W Thomsen, W Marieke Schoonen, Dóra K Farkas, Anders Riis, Jon P Fryzek, Henrik Toft Sørensen.   

Abstract

BACKGROUND: The extent and magnitude of mortality risk among patients splenectomised for a variety of indications is not well-described in the literature. We assessed mortality risk among splenectomised patients compared to the general population and to un-splenectomised patients with similar underlying medical conditions.
METHODS: We conducted a historical population-based cohort study in Denmark between January 1, 1996 and December 31, 2005. Mortality risk was evaluated within 90 days, 91-365 days, and >365 days post-splenectomy, controlling for age, sex, and comorbid conditions using Cox proportional hazards models for a splenectomised cohort compared to the general Danish population and a matched indication cohort.
RESULTS: We identified a total of 3812 splenectomised patients, 38,120 population comparisons, and 8310 matched indication comparisons. Within 90 days post-splenectomy, the adjusted relative risk (RR) for death, regardless of indication, was highly elevated compared to the general population: RR 33.6 [95% confidence interval (CI): 6.9, 35.0]. This risk declined substantially after 90 days post-splenectomy but remained higher 365 days post-splenectomy for all indications compared to the general population. When compared to the matched indication cohort, short- and long-term mortality risk with splenectomy was not increased.
CONCLUSION: Regardless of indication, the adjusted short- and long-term risk of death for splenectomised patients was higher than the general population. Most of this risk seems to be due to the underlying splenectomy indication and not to splenectomy alone. Copyright 2009 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20122606     DOI: 10.1016/j.ejim.2009.10.003

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.

Authors:  Rosarin Sruamsiri; Piyameth Dilokthornsakul; Chayanin Pratoomsoot; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

Review 2.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

3.  Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia.

Authors:  Soames Boyle; Richard H White; Ann Brunson; Ted Wun
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

4.  Risk of cardiovascular events and pulmonary hypertension following splenectomy - a Danish population-based cohort study from 1996-2012.

Authors:  Marianne Rørholt; Waleed Ghanima; Dora Körmendiné Farkas; Mette Nørgaard
Journal:  Haematologica       Date:  2017-06-01       Impact factor: 9.941

Review 5.  Post-splenectomy sepsis: preventative strategies, challenges, and solutions.

Authors:  Sarah Luu; Denis Spelman; Ian J Woolley
Journal:  Infect Drug Resist       Date:  2019-09-12       Impact factor: 4.003

Review 6.  Evolving treatment modalities for immune thrombocytopenia in adults.

Authors:  Sushmita Khadka; Vineela Kasireddy; Pravash Kumar Dhakal; Chandrakala Dadiboyina
Journal:  J Community Hosp Intern Med Perspect       Date:  2021-01-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.